FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments (FHIR)
Breast Cancer
About this trial
This is an interventional prevention trial for Breast Cancer focused on measuring Electronic Health Record, Decision Aid, Fast Healthcare Interoperability Resources (FHIR), Breast Cancer Risk Assessment, Lobular Carcinoma In Situ, Atypical Hyperplasia
Eligibility Criteria
Inclusion Criteria: Women, age 35-74 years High-risk defined as 5-year invasive breast cancer risk ≥1.7% or 10 risk ≥20% according to the BCSC or GAIL models English- or Spanish-speaking Able to sign informed consent. Exclusion Criteria: Women with a personal history of breast cancer Women who previously participated in a sub-study (Aim 1) of the awarded grant.
Sites / Locations
- Columbia University Irving Medical Center
Arms of the Study
Arm 1
Experimental
FHIR-Enhanced RealRisks
Participants will self-administer FHIR-enhanced RealRisks with access to risk communication games, family history pedigree and modules on chemoprevention and genetics testing, if relevant to them based on their risk and family history. The investigators are interested in gaining short-term feedback on patient activation and other patient reported outcomes, which will be assessed before and within 2 weeks after using RealRisks.